Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 12, 2008, Pages 3646-3651

  Myers, Michael C ^a   Shah, Parag P ^a   Beavers, Mary Pat ^a   Napper, Andrew D ^a   Diamond, Scott L ^a   Smith III, Amos B ^a   Huryn, Donna M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cathepsin L inhibitor; Cysteine protease; MLSCN; Oxocarbazate; Thiocarbazate

Indexed keywords

CATHEPSIN L; ENZYME INHIBITOR;

ARTICLE; CHEMICAL REACTION; DRUG DESIGN; DRUG DETERMINATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; MOLECULAR DOCKING;

BINDING SITES; CATHEPSINS; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDRAZINES; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PAPAIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS;

EID: 44649088214     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.065     Document Type: Article

References (41)

1. McGrath M.E. Annu. Rev. Biophys. Biomol. Struct. 28 (1999) 181
2. Lecaille F., Kaleta J., and Brömme D. Chem. Rev. 102 (2002) 4459
3. Vasiljeva O., Reinheckel T., Peters C., Turk D., Turk V., and Turk B. Curr. Pharm. Des. 13 (2007) 385
4. Felbor U., Dreier L., Bryant R.A.R., Ploegh H.L., Olsen B.R., and Mothes W. EMBO J. 19 (2000) 1187
5. Schedel J., Seemayer C.A., Pap T., Neidhart M., Kuchen S., Michel B.A., Gay R.E., Müller-Ladner U., Gay S., and Zacharias W. Gene Ther. 11 (2004) 1040
6. Esser R.E., Angelo R.A., Murphey M.D., Watts L.M., Thornburg L.P., Palmer J.T., Talhouk J.W., and Smith R.E. Arthritis Rheum. 37 (1994) 236
7. Hill P.A., Buttle D.J., Jones S.J., Boyde A., Murata M., Reynolds J.J., and Meikle M.C. J. Cell. Biochem. 56 (1994) 118
8. Chandran K., Sullivan N.J., Felbor U., Whelan S.P., and Cunningham J.M. Science 308 (2005) 1643
9. Schornberg K., Matsuyama S., Kabsch K., Delos S., Bouton A., and White J. J. Virol. 80 (2006) 4174
10. Kaletsky R.L., Simmons G., and Bates P. J. Virol. 81 (2007) 13378
11. Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., and Bates P. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11876
12. Rafati S., Salmanian A.-H., Hashemi K., Schaff C., Belli S., and Fasel N. Mol. Biochem. Parasitol. 113 (2001) 35
13. Myers M.C., Napper A.D., Motlekar N., Shah P.P., Chiu C.-H., Beavers M.P., Diamond S.L., Huryn D.M., and Smith III A.B. Bioorg. Med. Chem. Lett. 17 (2007) 4761
14. Penn Center for Molecular Discovery (PCMD): http://www.seas.upenn.edu/~pcmd/. Molecular Library Screening Center Network (MLSCN): http://nihroadmap.nih.gov/molecularlibraries/ Molecular Libraries Small Molecular Repository (MLSMR): http://mlsmr.glpg.com/MLSMR_HomePage/index.html PubChem: http://pubchem.ncbi.nlm.nih.gov/
15. Myers M.C., Shah P.P., Diamond S.L., Huryn D.M., and Smith III A.B. Bioorg. Med. Chem. Lett. 18 (2008) 210
16. Shah, P. P.; Myers, M. C.; Beavers, M. P.; Purvis, J. E.; Jing, H.; Grieser, H. J.; Sharlow, E. R.; Napper, A. D.; Huryn, D. M.; Cooperman, B. S.; Smith, A. B., III.; Diamond, S. L. Mol. Pharm., in press.
17. PubChem substance number for (-)-1 is SID 26681509.
18. Otto H.-H., and Schirmeister T. Chem. Rev. 97 (1997) 133
19. Schirmeister T., and Kaeppler U. Mini-Rev. Med. Chem. 3 (2003) 361
20. Hernandez A.A., and Roush W.R. Curr. Opin. Chem. Biol. 6 (2002) 459
21. Falgueyret J.-P., Oballa R.M., Okamoto O., Wesolowski G., Aubin Y., Rydzewski R.M., Prasit P., Riendeau D., Rodan S.B., and Percival M.D. J. Med. Chem. 44 (2001) 94
22. Marquis R.W., James I., Zeng J., Trout R.E.L., Thompson S., Rahman A., Yamashita D.S., Xie R., Gress C.J., Blake S., Lark M.A., Hwang S.-M., Tomaszek T., Offen P., Head M.S., Cummings M.D., and Veber D.F. J. Med. Chem. 48 (2005) 6870
23. Tsuge H., Nishimura T., Tada Y., Asao T., Turk D., Turk V., and Katunuma N. Biochem. Biophys. Res. Commun. 266 (1999) 411
24. Beavers, M. P.; Myers, M. C.; Shah, P. P.; Purvis, J. E.; Diamond, S. L.; Cooperman, B. S.; Huryn, D. M.; Smith, A. B., III., J. Chem. Inf. Model, in press.
25. General procedure to form amino acid-substituted thiocarbazates: Boc-protected amino acid hydrazide (1.0 mmol, 1.0 equiv) was added to a 25-mL round-bottomed flask followed by a solution of KOH in 95% EtOH (0.25 M, 4.4 mL, 1.1 equiv). After stirring for 5 min at 23 °C, a balloon of carbonyl sulfide gas was attached to the flask. The flask was purged with the gas (5 s) and a full balloon was reattached. The reaction was stirred for 15 h at 23 °C. After stirring overnight, the α-bromo anilide (1.1 mmol, 1.1 equiv) was added in one portion and the reaction was monitored by LC-MS. The α-bromo anilides were typically consumed within 20-60 min, and the reaction mixture was filtered, using a Büchner funnel. The filtrate was concentrated on a rotatory evaporator and purified by preparative reverse-phase HPLC.
26. 50 values in triplicate.
27. 2-Bromo-1-(3,4-dihydro-2H-quinolin-1-yl)-ethanone was used as the α-bromo anilide electrophile. For a general procedure for the preparation of α-bromo anilides, see:. von Geldern T.W., Tasker A.S., Sorensen B.K., Winn M., Szczepankiewicz B.G., Dixon D.B., Chiou W.J., Wang L., Wessale J.L., Adler A., Marsh K.C., Nguyen B., and Opgenorth T.J. J. Med. Chem. 42 (1999) 3668
28. (±)-3-Bromo-1-phenyl-2-pyrrolidinone was used as the α-bromo anilide electrophile. The resulting thiocarbazate 6 was assayed as a mixture of diastereomers.
29. Methyl bromoacetate was used as the α-bromo electrophile.
30. Magrath J., and Abeles R.H. J. Med. Chem. 35 (1992) 4279
31. Baggio R., Shi Y.-Q., Wu Y.-Q., and Abeles R.H. Biochemistry 35 (1996) 3351
32. Xing R., and Hanzlik R.P. J. Med. Chem. 41 (1998) 1344
33. Rich D.H., Brown M.A., and Barrett A.J. Biochem. J. 235 (1986) 731
34. Bondebjerg J., Fuglsang H., Valeur K.R., Kaznelson D.W., Hanse J.A., Pedersen R.O., Krogh B.O., Jensen B.S., Lauritzen C., Petersen G., Pedersen J., and Naerum L. Bioorg. Med. Chem. 13 (2005) 4408
35. The following standards were utilized as potential reaction products during the stoichiometric incubation of cathepsin L with (-)-1: L-Boc-Trp-NHNH2, N-(2-ethyl-phenyl)-2-mercapto-acetamide, and 2-ethyl-phenylamine.
36. For a general procedure for the preparation of succinanilic acids, see:. Kar A., and Argade N.P. Synthesis (2002) 221
37. Aza-peptides are commonly prepared from phosgene equivalents, resulting in a reactive isocyanate intermediate. For a representative example, see:. Boeglin D., and Lubell W.D. J. Comb. Chem. 7 (2005) 864
38. For a general procedure used to prepare oxocarbazates such as (-)-13, see: Fox, D. L.; Ruxer, J. T.; Oliver, J. M.; Alford, K. L., Salvatore, R. N. Tetrahedron Lett. 2004, 45, 401.
39. Dyker H., Scherkenbeck J., Gondol D., Goehrt A., and Harder A. J. Org. Chem. 66 (2001) 3760
40. PubChem substance number for (-)-13 is SID 46493575.
41. 6Na: 558.2329].